Edgewise Therapeutics, Inc. EWTX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$49.01M-20.1% | -$50.22M-26.6% | -$40.67M-19.2% | -$36.12M-14.7% | -$40.8M-43.0% | ||
| $537K+4.7% | $525K-9.0% | $500K0.0% | $500K0.0% | $513K+8.5% | ||
| $8.72M-3.8% | $9.88M+27.6% | $8.09M+17.5% | $7.73M+48.0% | $9.06M+86.0% | ||
| $1.45M-49.4% | —— | —— | —— | $2.86M+266% | ||
| -$6.75M-11.0% | $4.43M+14.5% | —— | —— | -$6.08M-120% | ||
| -$3.05M-306% | $2.72M+271% | $1.3M+264% | $2.47M+353% | $1.48M+2,246% | ||
| -$196K-9.5% | -$193K— | -$189K-5.6% | -$187K-9.4% | -$179K-9.1% | ||
| -$42.54M-12.4% | -$38.59M-43.2% | -$34.78M-27.0% | -$32.58M-24.8% | -$37.87M-32.4% | ||
| $260K+491% | $73K-73.4% | $105K-79.8% | $34K-84.6% | $44K-85.2% | ||
| $108.88M-28.0% | $108.19M+33.1% | —— | —— | $151.12M— | ||
| $2.43M-94.5% | —— | —— | -$162.17M— | $43.9M+116% | ||
| $12.17M+438% | —— | —— | $187.1M+2,482% | $2.26M-99.0% | ||
| —— | —— | —— | —— | $38K— | ||
| $12.17M+448% | $3.98M+37.3% | $1.66M-50.2% | $188.23M+9,543% | $2.22M-99.1% | ||
| -$27.94M-438% | $15.15M+582% | $2.6M— | —— | $8.26M+115% | ||
| $1.01M-47.3% | $1.48M-43.0% | $2.06M-36.5% | $2.2M-38.0% | $1.92M-39.0% | ||
| $537K+4.7% | $525K-9.0% | $500K0.0% | $500K0.0% | $513K+8.5% | ||
| -$6.75M-11.0% | $4.43M+14.5% | —— | —— | -$6.08M-120% | ||
| -$196K-9.5% | -$193K— | -$189K-5.6% | -$187K-9.4% | -$179K-9.1% | ||
| $635K+420% | $1.44M+30.8% | $548K-44.5% | -$1.42M-71.5% | $122K+220% | ||
| -$3.05M-306% | $2.72M+271% | $1.3M+264% | $2.47M+353% | $1.48M+2,246% | ||
| $3.97M-73.6% | $15.93M+418% | —— | —— | $15M— | ||
| —— | —— | —— | —— | $38K— | ||
| $41K— | $152K— | —— | —— | —— | ||
| $53K+29.3% | $50K-3.8% | $47K-25.4% | $44K-18.5% | $41K-21.2% | ||
| -$196K-9.5% | -$193K— | -$189K-5.6% | -$187K-9.4% | -$179K-9.1% | ||
| —— | —— | —— | —— | $395K— | ||
| -$42.8M-12.9% | -$38.67M-42.0% | -$34.88M-25.0% | -$32.62M-23.9% | -$37.91M-31.2% | ||
| -$42.8M-12.9% | -$38.67M-42.0% | -$34.88M-25.0% | -$32.62M-23.9% | -$37.91M-31.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Edgewise Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Edgewise Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.